Yang Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yang Zhang has a total of 205 co-authors. Here are the top co-authors by number of shared publications:
- Haiquan Chen
Department of Thoracic Surgery and State Key Laboratory of Genetics and Development of Complex Phenotypes, Fudan University Shanghai Cancer Center, Shanghai, China
111 shared publications - Xiaoming Zhang
National Key Laboratory of Immune Response and Immunotherapy, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Shanghai, China
63 shared publications - Yue Zhao
Departments of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China
63 shared publications - Zhiwei Cao
School of Life Sciences and Technology, Tongji University
63 shared publications - Fanfan Fan
Department of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China
62 shared publications - Jian Gao
Department of Thoracic Surgery and State Key Laboratory of Genetics and Development of Complex Phenotypes, Fudan University Shanghai Cancer Center, Shanghai, China
62 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Data from A Noninvasive Circulating Tumor DNA Methylation Classifier to Identify Benign Pulmonary Nodules
Purpose:Low-dose computed tomography suffers from a high false-positive rate in the evaluation of pulmonary nodules. Circulating tumor DNA (ctDNA) methylation is a promising complementary biomarker, but its detection is hindered by the highly fragmented nature of ctDNA. Experimental Design:We developed single-strand amplification methylation-targeted sequencing (SAMT-Seq), optimized for methylation detection in fragmented ctDNA. Lung cancer–specific methylation markers were identified from in-house cohort and The Cancer Genome Atlas database and validated in paired tissue and plasma samples from 30 patients with early-stage lung cancer. A panel of 30 key markers was selected using least absolute shrinkage and selection operator (LASSO) regression in a training cohort (n = 239). A Gaussian process classifier was developed and validated in two independent cohorts (n = 59 and n = 207). Results:SAMT-Seq demonstrated superior analytic sensitivity and on-target efficiency compared with a standard commercial Swift method. The 30-marker classifier yielded area under the curve values of 0.95, 0.95, and 0.92 in the training cohort and validation cohorts 1 and 2, respectively. Notably, it maintained robust performance across nodule types (solid/subsolid), sizes, smoking status, and in situ carcinoma. With a predefined threshold, the model achieved specificity of 100% and 92.16% in validation cohort 1 and 2, respectively, suggesting its potential utility in reducing false-positive classifications. Conclusions:We developed a high-specificity ctDNA methylation classifier that serves as a practical, complementary tool for risk stratification of pulmonary nodules, with the potential to significantly reduce unnecessary invasive procedures. Ongoing prospective diagnostic validation studies are evaluating its clinical performance.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Noninvasive Circulating Tumor DNA Methylation Classifier to Identify Benign Pulmonary Nodules
Purpose:Low-dose computed tomography suffers from a high false-positive rate in the evaluation of pulmonary nodules. Circulating tumor DNA (ctDNA) methylation is a promising complementary biomarker, but its detection is hindered by the highly fragmented nature of ctDNA. Experimental Design:We developed single-strand amplification methylation-targeted sequencing (SAMT-Seq), optimized for methylation detection in fragmented ctDNA. Lung cancer–specific methylation markers were identified from in-house cohort and The Cancer Genome Atlas database and validated in paired tissue and plasma samples from 30 patients with early-stage lung cancer. A panel of 30 key markers was selected using least absolute shrinkage and selection operator (LASSO) regression in a training cohort (n = 239). A Gaussian process classifier was developed and validated in two independent cohorts (n = 59 and n = 207). Results:SAMT-Seq demonstrated superior analytic sensitivity and on-target efficiency compared with a standard commercial Swift method. The 30-marker classifier yielded area under the curve values of 0.95, 0.95, and 0.92 in the training cohort and validation cohorts 1 and 2, respectively. Notably, it maintained robust performance across nodule types (solid/subsolid), sizes, smoking status, and in situ carcinoma. With a predefined threshold, the model achieved specificity of 100% and 92.16% in validation cohort 1 and 2, respectively, suggesting its potential utility in reducing false-positive classifications. Conclusions:We developed a high-specificity ctDNA methylation classifier that serves as a practical, complementary tool for risk stratification of pulmonary nodules, with the potential to significantly reduce unnecessary invasive procedures. Ongoing prospective diagnostic validation studies are evaluating its clinical performance.
- Open Access
- 9 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF12
A Noninvasive Circulating Tumor DNA Methylation Classifier to Identify Benign Pulmonary Nodules
Purpose: Low-dose computed tomography suffers from a high false-positive rate in the evaluation of pulmonary nodules. Circulating tumor DNA (ctDNA) methylation is a promising complementary biomarker, but its detection is hindered by the highly fragmented nature of ctDNA. Experimental Design: We developed single-strand amplification methylation-targeted sequencing (SAMT-Seq), optimized for methylation detection in fragmented ctDNA. Lung cancer–specific methylation markers were identified from in-house cohort and The Cancer Genome Atlas database and validated in paired tissue and plasma samples from 30 patients with early-stage lung cancer. A panel of 30 key markers was selected using least absolute shrinkage and selection operator (LASSO) regression in a training cohort (n = 239). A Gaussian process classifier was developed and validated in two independent cohorts (n = 59 and n = 207). Results: SAMT-Seq demonstrated superior analytic sensitivity and on-target efficiency compared with a standard commercial Swift method. The 30-marker classifier yielded area under the curve values of 0.95, 0.95, and 0.92 in the training cohort and validation cohorts 1 and 2, respectively. Notably, it maintained robust performance across nodule types (solid/subsolid), sizes, smoking status, and in situ carcinoma. With a predefined threshold, the model achieved specificity of 100% and 92.16% in validation cohort 1 and 2, respectively, suggesting its potential utility in reducing false-positive classifications. Conclusions: We developed a high-specificity ctDNA methylation classifier that serves as a practical, complementary tool for risk stratification of pulmonary nodules, with the potential to significantly reduce unnecessary invasive procedures. Ongoing prospective diagnostic validation studies are evaluating its clinical performance.
- 9 June 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF12
Open AccessA Noninvasive Circulating Tumor DNA Methylation Classifier to Identify Benign Pulmonary Nodules
Purpose: Low-dose computed tomography suffers from a high false-positive rate in the evaluation of pulmonary nodules. Circulating tumor DNA (ctDNA) methylation is a promising complementary biomarker, but its detection is hindered by the highly fragmented nature of ctDNA. Experimental Design: We developed single-strand amplification methylation-targeted sequencing (SAMT-Seq), optimized for methylation detection in fragmented ctDNA. Lung cancer–specific methylation markers were identified from in-house cohort and The Cancer Genome Atlas database and validated in paired tissue and plasma samples from 30 patients with early-stage lung cancer. A panel of 30 key markers was selected using least absolute shrinkage and selection operator (LASSO) regression in a training cohort (n = 239). A Gaussian process classifier was developed and validated in two independent cohorts (n = 59 and n = 207). Results: SAMT-Seq demonstrated superior analytic sensitivity and on-target efficiency compared with a standard commercial Swift method. The 30-marker classifier yielded area under the curve values of 0.95, 0.95, and 0.92 in the training cohort and validation cohorts 1 and 2, respectively. Notably, it maintained robust performance across nodule types (solid/subsolid), sizes, smoking status, and in situ carcinoma. With a predefined threshold, the model achieved specificity of 100% and 92.16% in validation cohort 1 and 2, respectively, suggesting its potential utility in reducing false-positive classifications. Conclusions: We developed a high-specificity ctDNA methylation classifier that serves as a practical, complementary tool for risk stratification of pulmonary nodules, with the potential to significantly reduce unnecessary invasive procedures. Ongoing prospective diagnostic validation studies are evaluating its clinical performance.
- 5 June 2026
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 21 (11) , 103965
The Prognostic Impact of Common Molecular Alterations in Resected Lung Adenocarcinoma and Implications for the Tenth Edition TNM Classification
- 5 June 2026
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 21 (11) , 103965
The Prognostic Impact of Common Molecular Alterations in Resected Lung Adenocarcinoma and Implications for the Tenth Edition TNM Classification
- 25 May 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 225, 105386
Mitophagy in lymph node metastasis: Mechanisms, immune consequences and therapeutic opportunities
- 25 May 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 225, 105386
Mitophagy in lymph node metastasis: Mechanisms, immune consequences and therapeutic opportunities
- Open Access
- 11 May 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (5) , e014437
Simplified perioperative serplulimab and chemotherapy for resectable squamous NSCLC: a phase II trial with biomarker analysis
Purpose: Squamous non-small cell lung cancer (sq-NSCLC) is a distinct subtype of NSCLC. This exploratory, phase II study investigated the feasibility and efficacy of a four-cycle perioperative regimen combining serplulimab with a taxane (paclitaxel or nab-paclitaxel) and carboplatin in patients with resectable stage II-IIIA sq-NSCLC. Methods: This investigator-initiated, single-arm, phase II exploratory trial ( NCT05775796 ) enrolled patients with histologically confirmed, resectable clinical stage II-IIIA squamous NSCLC. Patients received two to three cycles of neoadjuvant serplulimab plus taxane-carboplatin, followed by curative-intent surgery and one to two cycles of adjuvant treatment. The primary endpoint was major pathological response (MPR). Secondary endpoints included pathological complete response (pCR), R0 resection rate, overall response rate (ORR), safety, event-free survival (EFS), and overall survival (OS). Results: A total of 30 patients without actionable driver alterations were enrolled and 29 underwent surgery. The median age was 65 years, and most were male smokers (n=28, 93.33%). Surgery was performed in 29 patients, and R0 resection was achieved in 96.55% (28/29) of the surgically resected patients. Among all enrolled patients, MPR and pCR rates were 76.67% and 50.00%, respectively. Based on radiological assessments during the neoadjuvant phase, the ORR was 73.33% (95% CI 54.11% to 87.72%). Grade ≥3 treatment-related adverse events were predominantly hematologic and were generally manageable. Long-term EFS and OS data are not yet mature. Additionally, exploratory minimal residual disease analysis using circulating tumor DNA (ctDNA) in 27 patients showed a strong correlation between ctDNA clearance and pCR (p=0.004), suggesting ctDNA as a promising biomarker for immunochemotherapy response. Conclusions: A four-cycle perioperative regimen of serplulimab combined with taxane-carboplatin demonstrated promising MPR and pCR rates with an acceptable safety profile in patients with resectable sq-NSCLC. Long-term follow-up and future phase III trials are warranted to confirm these exploratory findings. Trial registration number: NCT05775796 .
- 11 May 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (5) , e014437
Open AccessSimplified perioperative serplulimab and chemotherapy for resectable squamous NSCLC: a phase II trial with biomarker analysis
Purpose: Squamous non-small cell lung cancer (sq-NSCLC) is a distinct subtype of NSCLC. This exploratory, phase II study investigated the feasibility and efficacy of a four-cycle perioperative regimen combining serplulimab with a taxane (paclitaxel or nab-paclitaxel) and carboplatin in patients with resectable stage II-IIIA sq-NSCLC. Methods: This investigator-initiated, single-arm, phase II exploratory trial ( NCT05775796 ) enrolled patients with histologically confirmed, resectable clinical stage II-IIIA squamous NSCLC. Patients received two to three cycles of neoadjuvant serplulimab plus taxane-carboplatin, followed by curative-intent surgery and one to two cycles of adjuvant treatment. The primary endpoint was major pathological response (MPR). Secondary endpoints included pathological complete response (pCR), R0 resection rate, overall response rate (ORR), safety, event-free survival (EFS), and overall survival (OS). Results: A total of 30 patients without actionable driver alterations were enrolled and 29 underwent surgery. The median age was 65 years, and most were male smokers (n=28, 93.33%). Surgery was performed in 29 patients, and R0 resection was achieved in 96.55% (28/29) of the surgically resected patients. Among all enrolled patients, MPR and pCR rates were 76.67% and 50.00%, respectively. Based on radiological assessments during the neoadjuvant phase, the ORR was 73.33% (95% CI 54.11% to 87.72%). Grade ≥3 treatment-related adverse events were predominantly hematologic and were generally manageable. Long-term EFS and OS data are not yet mature. Additionally, exploratory minimal residual disease analysis using circulating tumor DNA (ctDNA) in 27 patients showed a strong correlation between ctDNA clearance and pCR (p=0.004), suggesting ctDNA as a promising biomarker for immunochemotherapy response. Conclusions: A four-cycle perioperative regimen of serplulimab combined with taxane-carboplatin demonstrated promising MPR and pCR rates with an acceptable safety profile in patients with resectable sq-NSCLC. Long-term follow-up and future phase III trials are warranted to confirm these exploratory findings. Trial registration number: NCT05775796 .
- Open Access
- 5 May 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Feasibility of Wedge Resection for Subpleural Hilar Lung Nodules Using CT-guided Hookwire Localization and Ultrasonic Dissection
Objective: To evaluate the safety and efficiency of a novel computed tomography (CT)-guided hookwire localization technique, aiming to enable parenchyma-sparing wedge resection using video-assisted thoracoscopic surgery (VATS) for small, hilar-proximal, ground-glass opacity (GGO)-dominant nodules. Summary Background Data: Localizing hilar-proximal GGOs remains challenging. For small, hilar-proximal, GGO-dominant lung nodules, there is no consensus regarding the optimal surgical approach. Methods: This was a multicenter retrospective study from January 2023 to July 2025 including 79 patients with subpleural pulmonary nodules ≤ 2 cm in diameter and consolidation-to-tumor ratio (CTR) ≤ 0.25 located near the hilum. Patients underwent preoperative CT-guided hookwire localization using transfissural or traversing-lobe approach, followed by uniportal VATS wedge resection. Resection was performed using ultrasonic dissection with limited stapler use to maximize lung preservation. Results: 79 nodules (median, 7 mm, range 6-20 mm) were successfully localized. Minor asymptomatic pneumothorax occurred after localization in 12 patients and small pulmonary hemorrhage in 10 patients. The median operative time was 15.0 minutes (range 10-28 minutes). Histopathology confirmed 9 adenocarcinoma in situ, 53 minimally invasive adenocarcinoma, 14 invasive adenocarcinoma, and 3 benign lesions. 10 patients experienced persistent air leak > 72h and no other major complications occurred. Median postoperative hospital stay was 3 days (range 2 – 6 d). At a median follow-up of 17.3 months, no local recurrences or deaths have been detected. Conclusions: This novel CT-guided hookwire localization strategy proved highly effective for small, hilar-proximal, GGO-dominant lung nodules, facilitating their successful removal by VATS wedge resection with parenchyma-sparing technique.
- 5 May 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Open AccessFeasibility of Wedge Resection for Subpleural Hilar Lung Nodules Using CT-guided Hookwire Localization and Ultrasonic Dissection
Objective: To evaluate the safety and efficiency of a novel computed tomography (CT)-guided hookwire localization technique, aiming to enable parenchyma-sparing wedge resection using video-assisted thoracoscopic surgery (VATS) for small, hilar-proximal, ground-glass opacity (GGO)-dominant nodules. Summary Background Data: Localizing hilar-proximal GGOs remains challenging. For small, hilar-proximal, GGO-dominant lung nodules, there is no consensus regarding the optimal surgical approach. Methods: This was a multicenter retrospective study from January 2023 to July 2025 including 79 patients with subpleural pulmonary nodules ≤ 2 cm in diameter and consolidation-to-tumor ratio (CTR) ≤ 0.25 located near the hilum. Patients underwent preoperative CT-guided hookwire localization using transfissural or traversing-lobe approach, followed by uniportal VATS wedge resection. Resection was performed using ultrasonic dissection with limited stapler use to maximize lung preservation. Results: 79 nodules (median, 7 mm, range 6-20 mm) were successfully localized. Minor asymptomatic pneumothorax occurred after localization in 12 patients and small pulmonary hemorrhage in 10 patients. The median operative time was 15.0 minutes (range 10-28 minutes). Histopathology confirmed 9 adenocarcinoma in situ, 53 minimally invasive adenocarcinoma, 14 invasive adenocarcinoma, and 3 benign lesions. 10 patients experienced persistent air leak > 72h and no other major complications occurred. Median postoperative hospital stay was 3 days (range 2 – 6 d). At a median follow-up of 17.3 months, no local recurrences or deaths have been detected. Conclusions: This novel CT-guided hookwire localization strategy proved highly effective for small, hilar-proximal, GGO-dominant lung nodules, facilitating their successful removal by VATS wedge resection with parenchyma-sparing technique.
- Open Access
- 1 April 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (4) , 80
Preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT)-based strategy for predicting negative mediastinal lymph node metastasis status in non-small cell lung cancer
Original Article Preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT)-based strategy for predicting negative mediastinal lymph node metastasis status in non-small cell lung cancer Juntian Yao, Fangqiu Fu, Nan Li, Chaoqiang Deng, Shaoli Song, Yang Zhang, Haiquan Chen
- 1 April 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (4) , 80
Open AccessPreoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT)-based strategy for predicting negative mediastinal lymph node metastasis status in non-small cell lung cancer
Original Article Preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT)-based strategy for predicting negative mediastinal lymph node metastasis status in non-small cell lung cancer Juntian Yao, Fangqiu Fu, Nan Li, Chaoqiang Deng, Shaoli Song, Yang Zhang, Haiquan Chen
- Open Access
- 1 April 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (4) , 92
The IASLC grading system as a predictor for EGFR-TKI therapy in patients with EGFR-mutant lung adenocarcinoma
Original Article The IASLC grading system as a predictor for EGFR-TKI therapy in patients with EGFR-mutant lung adenocarcinoma Chaoqiang Deng, Molin Zhang, Fangqiu Fu, Qiang Zheng, Yuan Li, Yang Zhang, Haiquan Chen
- 1 April 2026
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 15 (4) , 92
Open AccessThe IASLC grading system as a predictor for EGFR-TKI therapy in patients with EGFR-mutant lung adenocarcinoma
Original Article The IASLC grading system as a predictor for EGFR-TKI therapy in patients with EGFR-mutant lung adenocarcinoma Chaoqiang Deng, Molin Zhang, Fangqiu Fu, Qiang Zheng, Yuan Li, Yang Zhang, Haiquan Chen